Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CEROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CEROW SEC filings page on Stock Titan aggregates regulatory documents for CERo Therapeutics Holdings, Inc., giving investors direct access to the company’s official disclosures. CERo identifies itself in its S-1 as a Delaware corporation in the biological products sector, an emerging growth company and a smaller reporting company, and its filings describe a business centered on drug candidates, preclinical studies and clinical trials, including work on CER-1236.
Key filings include multiple Form 8-K current reports. An 8-K dated January 7, 2026 describes a press release providing a clinical update on a Phase 1 trial of CER-1236 in AML (CertainT-1), highlighting safety data and a platelet transfusion-free interval observed in a patient with myelodysplastic syndrome/AML. Other 8-Ks filed in December 2025 detail a new common stock purchase agreement and related registration rights agreement with an institutional investor, continuing an equity line program for the company’s common stock.
The page also includes Form S-1 registration statements. In its December 2025 S-1, CERo explains that its common stock is traded on the OTCQB under the symbol "CERO" and outlines the potential resale by Keystone Capital Partners, LLC of shares issued under common stock purchase agreements that form an equity financing arrangement. The S-1 discusses the committed equity financing structure, prior registration statements and the role of Keystone as a selling securityholder.
In addition, proxy materials such as the definitive proxy statement on Schedule 14A provide detail on proposed amendments to the certificate of incorporation for a reverse stock split, approval of issuances under Nasdaq Listing Rule 5635, and amendments to the 2024 Equity Incentive Plan. On Stock Titan, these filings are presented with AI-powered summaries that highlight the main topics of each document, helping readers quickly identify items related to clinical development, financing arrangements, capital structure changes and governance proposals, while still allowing full-text review of the underlying SEC reports.
CERO THERAPEUTICS HOLDINGS, INC. reports that Isaiah Tibbs beneficially owns 1,830,007 shares of Common Stock, representing 8.67% of the class. The filing states Tibbs has sole power to vote and sole dispositive power over all 1,830,007 shares.
CERO Therapeutics Holdings, Inc. entered into a financing agreement by issuing a convertible promissory note to Keystone Capital Partners for a $750,000 purchase price with a principal face value of $937,500, allowing total borrowings up to $1,000,000. The note bears 10% annual interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership limit. The company plans to file a registration statement covering resale of conversion shares. CERO’s audit committee dismissed Wolf & Company, P.C. as independent auditor and appointed Salberg & Company, P.A., following prior audit reports that included a going concern explanatory paragraph and a material weakness in internal controls. The board also expanded from six to seven members and appointed Eric Francois as a new director, with an expectation he will stand for election at the 2026 annual meeting.
CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.
The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.
CERO Therapeutics Holdings, Inc. reported that the Nasdaq Listing and Hearing Review Council has affirmed a prior decision to delist the company’s securities from the Nasdaq Stock Market. The Council’s decision, dated January 29, 2026, upholds a panel ruling following an earlier trading suspension effective October 31, 2025.
This means the company’s common stock and related warrants will no longer trade on Nasdaq, which can affect trading liquidity and market visibility for shareholders. The filing does not describe any alternative listing venue in this excerpt.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.
CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.
Cero Therapeutics Holdings director reports large stock option award
Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., reported receiving a stock option covering 1,612,099 shares of the company’s common stock. The option has an exercise price of $0.055 per share, meaning he can buy up to that number of shares at this fixed price.
The option became exercisable on January 7, 2026 and is scheduled to expire on January 6, 2036, giving a 10‑year exercise window. Following this transaction, Atwood beneficially owns 1,612,099 derivative securities in the form of this stock option, which is reported as held directly.
Cero Therapeutics Holdings, Inc. reported that Chairman and CEO Christopher B. Ehrlich received a large stock option grant. On January 7, 2026, he was awarded a stock option to buy 4,530,997 shares of common stock at an exercise price of $0.055 per share. The option is exercisable from January 7, 2026 and expires on January 6, 2036. Following this grant, he beneficially owns 4,530,997 derivative securities, held as a direct ownership position, and there was no cash price paid for the option itself.